PDL1 Antibody [1D7] Cat. No.: RF16038

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
HOST SPECIES:Mouse
SPECIES REACTIVITY: Human
IMMUNOGEN: PD-L1 antibody was raised against the extracellular domain of human PD-L1.
TESTED APPLICATIONS: ELISA, ICC, IF, IHC-P, WB
APPLICATIONS: PD-L1 antibody can be used for detection of PD-L1 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 5μg/mL.

Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
POSITIVE CONTROL:1) Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate
 2) Cat. No. 1315 - Human Tonsil Tissue
PREDICTED MOLECULAR WEIGHT: Predicted: 32 kDa

Observed: 45 kDa

psi-iconProperties
PURIFICATION:PD-L1 Antibody is supplied as protein A purified IgG1.
CLONALITY:Monoclonal
ISOTYPE:IgG1
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:PD-L1 Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:PD-L1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:CD274
ALTERNATE NAMES:PD-L1 Antibody: Programmed cell death 1 ligand-1, programmed death ligand 1, PDL1, PDL-1, B7-H1
ACCESSION NO.:NP_054862
PROTEIN GI NO.:7661534
GENE ID:29126
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).
REFERENCES:1) Holling TM, Schooten E, and van Den Elsing PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol. 2004; 65:282-90.
2) Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11:3887-95.
3) LaGier J and Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum. Immunol. 2006; 67:568-78.
4) Aydin AM, Woldu SL, Hutchinson RC, et al. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Onco. Targets Ther. 2017;10:1487-502.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.